Gilead Sciences Inc buy klostergang
Summary
This prediction ended on 07.12.15 with a price of €96.14. With a performance of 8.86%, the BUY prediction by klostergang for Gilead Sciences Inc closed with a slight gain. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Gilead Sciences Inc | -2.068% | -2.068% | -17.502% | 16.945% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
According to klostergang what are the pros and cons of Gilead Sciences Inc for the foreseeable future?
Pros
Cons
Comments by klostergang for this prediction
In the thread Gilead Sciences Inc diskutieren
Gilead ist und bleibt ein Basisinvestment im Biotech-Bereich
Gilead hat im Verhältnis zu anderen Biotech-Werten eines der stärksten Medikamenten-Portfolios, wobei allein Sovaldi 10,3 Milliarden Dollar im Jahr 2014 und Harvoni 2,1 Milliarden im ersten Quartal seit Verkauf zum Umsatz beisteuerten. Seit der Zulassung hat Gilead 140.000 HCV-Patienten im Jahr 2014 behandelt, und wird voraussichtlich im Jahr 2015 mindestens 250.000 behandeln können.
Das Unternehmen verfügt über eines der robustesten Pipelines. 21 Produkte mit Marktzulassung, mehr als 250 laufende und geplante klinischen Studien, sieben davon in Phase 3. Besonders zu erwähnen sind in Phase 2 Simtuzumab für Fibrose und GS-4997 für Diabetische Nephropathie, die bei erfolgreicher Kommerzialisierung einen Multi-Milliarden-Dollar-Umsatz ermöglichen.
Biotech experiences a significant selloff.
This selloff, based on Clinton's remarks, seems unjustified.
Gilead will show good Q3 results and has good candidates in its pipeline.
Gilead trades at a very low valuation.
Selloff looks like a good buying opportunity.
Gilead's new drug developments are encouraging as well: With its TAF HIV regimen, Gilead continues to be the leader in HIV treatment, which should help protect the company's market share here. Additionally, Gilead is on track to get a pan-genotypic single-tablet HCV regimen on the market.
Right now Gilead's single-tablet regimen (Harvoni) is only approved for HCV genotype 1, and the introduction of a better tablet would help Gilead to protect market share (and expand revenues) for the treatment of genotypes 2 to 6 (albeit they are less common and therefore less important than genotype 1).
Gilead thus looks like a good pick right now, with strong growth from the drugs already on the market, and with a strong pipeline as well (which includes a lot of other drug candidates, too).
Yet, Gilead is trading at a very low valuation right now.
Stopped prediction by klostergang for Gilead Sciences Inc
Gilead Sciences Inc
29.03.20
04.11.21
17.06.21
